The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use

  • Lim, Mie Jin (Division of Rheumatology, Department of Internal Medicine, Inha University Hospital) ;
  • Kwon, Seong Ryul (Division of Rheumatology, Department of Internal Medicine, Inha University Hospital) ;
  • Joo, Kowoon (Division of Rheumatology, Department of Internal Medicine, Inha University Hospital) ;
  • Son, Min Jung (Division of Rheumatology, Department of Internal Medicine, Inha University Hospital) ;
  • Park, Shin-Goo (Department of Occupational and Environmental Medicine, Inha University Hospital) ;
  • Park, Won (Division of Rheumatology, Department of Internal Medicine, Inha University Hospital)
  • Received : 2013.03.19
  • Accepted : 2014.10.02
  • Published : 2014.11.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. Methods: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). Results: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARD-naive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from $1.67{\pm}2.12pg/mL$ at baseline to $2.51{\pm}3.03pg/mL$, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). Conclusions: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.

Keywords

Acknowledgement

Supported by : Inha University

References

  1. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-251. https://doi.org/10.1111/j.0105-2896.2005.00338.x
  2. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009;68:373-376. https://doi.org/10.1136/ard.2008.091611
  3. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, de- Vernejoul MC, Boissier MC, Cohen-Solal ME. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004;35:1200-1207. https://doi.org/10.1016/j.bone.2004.07.004
  4. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163. https://doi.org/10.1038/nm1538
  5. Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008;35:2313-2315. https://doi.org/10.3899/jrheum.080356
  6. Vis M, Wolbink GJ, Lodder MC, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 2003;48:2996-2997. https://doi.org/10.1002/art.11292
  7. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-1499. https://doi.org/10.1136/ard.2005.044198
  8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  9. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. https://doi.org/10.1002/art.1780390105
  10. Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy. J Rheumatol 2001;28:251-256.
  11. Torikai E, Kageyama Y, Takahashi M, Nagano A. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Mod Rheumatol 2006;16:350-354. https://doi.org/10.3109/s10165-006-0517-z
  12. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464-470.
  13. Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103. https://doi.org/10.1007/PL00005830
  14. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-19887. https://doi.org/10.1074/jbc.M413274200
  15. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005;280:26770-26775. https://doi.org/10.1074/jbc.M504308200
  16. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006;21:1738-1749. https://doi.org/10.1359/jbmr.060810
  17. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 2008;90 Suppl 1:31-35. https://doi.org/10.2106/JBJS.G.01183
  18. Yasunori K, Masaaki T, Tetsuyuki N, Hayato K, Akira N. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:1093-1101. https://doi.org/10.1007/s10067-008-0870-8
  19. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women: the six-month effect of risedronate and teriparatide. Osteoporos Int 2012;23:1171-1176. https://doi.org/10.1007/s00198-010-1525-6
  20. Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:921-925.
  21. Modder UI, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011;26:27-34. https://doi.org/10.1002/jbmr.128
  22. Sennels H, Sorensen S, Ostergaard M, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 2008;37:241-247. https://doi.org/10.1080/03009740801910320

Cited by

  1. Bone and TNF in rheumatoid arthritis: clinical implications vol.1, pp.1, 2014, https://doi.org/10.1136/rmdopen-2015-000065
  2. Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis vol.98, pp.6, 2014, https://doi.org/10.1007/s00223-016-0114-x
  3. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis vol.2017, pp.None, 2014, https://doi.org/10.1155/2017/2690402
  4. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis vol.39, pp.1, 2014, https://doi.org/10.1007/s10067-019-04771-3
  5. Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study vol.40, pp.3, 2014, https://doi.org/10.1007/s00296-019-04418-1